It suggests that precise intervention targeting the C2_STAT1+ subpopulation may break through the dilemma of immune escape and broad-spectrum drug resistance in EGFR/TP53 co-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.